If these preclinical studies are successful, the researchers plan to further develop their CAR T cell therapy and
test its safety and efficacy
for different types of metastatic
cancer in upcoming clinical trials.
Beyond the expansion
of the collection
of barcoded cell lines
for testing larger panels
of compounds, next steps will include determining whether PRISM can be used to study the complex interactions between
different cell
types found within tumors, or to study tumor evolution during
cancer development or after
cancer treatment.
Because the region
of chromosome 5p15 is
of interest in
cancer biology, the deCODE team then
tested this SNP
for association with 16
different types of cancer in a total
of nearly 80,000
cancer patients and healthy control subjects from Iceland, the Netherlands, Italy, Sweden, Spain, Germany, Hungary, the United Kingdom, Belgium, Romania, Slovakia and the United States.